HROW Harrow, Inc.
HROW Harrow, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $39.16 · VWAP $39.22 · -30.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
HROW Price Structure
Loading timeframes…
Peers
Every watchlist HROW belongs to, members best 30-day change first — HROW highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare
Harrow furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How HROW's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about HROW from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Oct 3
- HROW - Harrow Inc Earnings Reports, Summaries & Call Transcripts | Morningstar
- Imprimis Stock Price Today | NASDAQ: HROW Live - Investing.com
- HROW | Imprimis Share Price - Investing.com NG
- Harrow Announces Second Quarter 2026 Financial Results | Harrow, Inc.
- Harrow (HROW) Stock Price, Quote, News & History | Benzinga
HROW research tape
45 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.